1-241497927-AT-ATTTT

Variant summary

Our verdict is Likely benign. Variant got -1 ACMG points: 4P and 5B. PM1PM4_SupportingPP5BS1_SupportingBS2

The NM_000143.4(FH):​c.1431_1433dupAAA​(p.Lys477dup) variant causes a disruptive inframe insertion change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00191 in 1,613,964 control chromosomes in the GnomAD database, including 8 homozygotes. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. N478N) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0010 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0020 ( 8 hom. )

Consequence

FH
NM_000143.4 disruptive_inframe_insertion

Scores

Not classified

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:17U:8B:1O:1

Conservation

PhyloP100: 1.41
Variant links:
Genes affected
FH (HGNC:3700): (fumarate hydratase) The protein encoded by this gene is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate. It exists in both a cytosolic form and an N-terminal extended form, differing only in the translation start site used. The N-terminal extended form is targeted to the mitochondrion, where the removal of the extension generates the same form as in the cytoplasm. It is similar to some thermostable class II fumarases and functions as a homotetramer. Mutations in this gene can cause fumarase deficiency and lead to progressive encephalopathy. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -1 ACMG points.

PM1
In a hotspot region, there are 3 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 1 benign, 12 uncertain in NM_000143.4
PM4
Nonframeshift variant in NON repetitive region in NM_000143.4. Strenght limited to Supporting due to length of the change: 1aa.
PP5
Variant 1-241497927-A-ATTT is Pathogenic according to our data. Variant chr1-241497927-A-ATTT is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 42095.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=7, Pathogenic=6, Likely_benign=1, not_provided=1, Likely_pathogenic=7}.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.00103 (157/152284) while in subpopulation NFE AF= 0.00162 (110/68016). AF 95% confidence interval is 0.00137. There are 0 homozygotes in gnomad4. There are 61 alleles in male gnomad4 subpopulation. Median coverage is 31. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High AC in GnomAd4 at 157 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
FHNM_000143.4 linkc.1431_1433dupAAA p.Lys477dup disruptive_inframe_insertion 10/10 ENST00000366560.4 NP_000134.2 P07954-1A0A0S2Z4C3

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
FHENST00000366560.4 linkc.1431_1433dupAAA p.Lys477dup disruptive_inframe_insertion 10/101 NM_000143.4 ENSP00000355518.4 P07954-1

Frequencies

GnomAD3 genomes
AF:
0.00103
AC:
157
AN:
152166
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.000314
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000458
Gnomad ASJ
AF:
0.00547
Gnomad EAS
AF:
0.000192
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.000283
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00162
Gnomad OTH
AF:
0.00191
GnomAD3 exomes
AF:
0.00104
AC:
259
AN:
249492
Hom.:
2
AF XY:
0.000992
AC XY:
134
AN XY:
135066
show subpopulations
Gnomad AFR exome
AF:
0.000369
Gnomad AMR exome
AF:
0.000492
Gnomad ASJ exome
AF:
0.00516
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000139
Gnomad NFE exome
AF:
0.00150
Gnomad OTH exome
AF:
0.00212
GnomAD4 exome
AF:
0.00201
AC:
2933
AN:
1461680
Hom.:
8
Cov.:
31
AF XY:
0.00197
AC XY:
1430
AN XY:
727144
show subpopulations
Gnomad4 AFR exome
AF:
0.000418
Gnomad4 AMR exome
AF:
0.000403
Gnomad4 ASJ exome
AF:
0.00520
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.0000936
Gnomad4 NFE exome
AF:
0.00235
Gnomad4 OTH exome
AF:
0.00237
GnomAD4 genome
AF:
0.00103
AC:
157
AN:
152284
Hom.:
0
Cov.:
31
AF XY:
0.000819
AC XY:
61
AN XY:
74474
show subpopulations
Gnomad4 AFR
AF:
0.000313
Gnomad4 AMR
AF:
0.000458
Gnomad4 ASJ
AF:
0.00547
Gnomad4 EAS
AF:
0.000193
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.000283
Gnomad4 NFE
AF:
0.00162
Gnomad4 OTH
AF:
0.00189
Alfa
AF:
0.00247
Hom.:
0
Bravo
AF:
0.00111
Asia WGS
AF:
0.000289
AC:
1
AN:
3476
EpiCase
AF:
0.00196
EpiControl
AF:
0.00196

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:17Uncertain:8Benign:1Other:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Pathogenic:10Uncertain:4
Uncertain significance, criteria provided, single submitterclinical testingGreenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic CenterJan 28, 2021PM3, PM4 -
Pathogenic, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
Pathogenic, criteria provided, single submitterclinical testingGeneDxFeb 27, 2024In-frame duplication of 1 amino acid in a non-repeat region; Recent studies suggest that in the heterozygous state, this variant is not associated with an increased risk to develop HLRCC-related tumors (PMID: 31444830, 33166576, 34994643); This variant has been observed as homozygous in asymptomatic adults tested at GeneDx and in large population cohorts (gnomAD; internal data), suggesting this variant is not associated with FHD when present in the homozygous state; In silico analysis supports a deleterious effect on protein structure/function; Also known as 1302insAAA, Lys434ins, insK477, 435insK, and 435insAAA; This variant is associated with the following publications: (PMID: 28748451, 27051561, 23612258, 2314594, 29319699, 31942411, 31831373, 16151915, 9300800, 9635293, 15987702, 20301679, 27621404, 20549362, 28873162, 29506128, 12761039, 16237213, 28825054, 29641532, 22703879, 18313410, 25985877, 16639410, 21560188, 24441663, 24182348, 16510303, 27541980, 30256826, 29909963, 30426508, 31212687, 28552549, 31444830, 32782288, 31980526, 32581362, 33789101, 33166576, 32413184, 32012241, 33363901, 35626031, 34308104, 35441217, 34289891, 33858029, 31794323, 34994643, 34337822, 35993574, 36556183, 32999401, 29893455, 36773955, 36777509, 33439686, 37255402, 36947458) -
Likely pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 31, 2024This variant, c.1431_1433dup, results in the insertion of 1 amino acid(s) of the FH protein (p.Lys477dup), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs367543046, gnomAD 0.5%), including at least one homozygous and/or hemizygous individual. This variant has been observed in combination with other pathogenic FH variants in multiple individuals with autosomal recessive fumarate hydratase deficiency (FHD) (PMID: 9300800, 9635293, 23612258, 16510303, 16151915, 24182348, 27541980, Invitae). However, individuals who are homozygous for this variant do not have clinical features of FHD (gnomAD, Invitae, external communication). It has also been observed as heterozygous in a few individuals with features suggestive of autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC), as well as in unaffected controls (PMID: 23612258, 16639410, 24441663, 25985877, 22703879, Invitae). This variant is also known as c.1433_1434insAAA, c.1431insAAA, c.1433_1434dupAAA, AAAins435, 435insK, InsK477, and 435insAAA. ClinVar contains an entry for this variant (Variation ID: 42095). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that patient cells carrying this variant and another loss-of-function FH variant have significantly reduced fumarate hydratase enzyme activity (0-20%), compared to wild-type cells (PMID: 9300800, 9635293, 15987702, 16151915, 24182348). No in vitro functional studies measuring the enzymatic activity of this variant alone have been performed. In summary, this is an in-frame duplication that has been observed with several different pathogenic FH variants in multiple affected individuals with FHD. In the homozygous state, this variant does not likely cause FHD, but additional data are needed to prove that conclusively. Although it has been observed as heterozygous in individuals with features of HLRCC, it occurs in the general population too frequently given the rarity of this condition. For these reasons, this variant has been classified as Likely Pathogenic for FHD. However, it is not likely to confer risk for HLRCC. -
Likely pathogenic, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoMar 19, 2020DNA sequence analysis of the FH gene demonstrated a three base pair duplication in exon 10, c.1431_1433dup. This pathogenic sequence change results in the duplication of one amino acid residue, p.Lys477dup. The p.Lys477dup sequence change is the most frequent mutant allele observed in patients with autosomal recessive FH-associated fumarate hydratase deficiency (PMID: 20301679). Functional studies have shown that the p.Lys477dup sequence change leads to significantly reduced FH enzyme activity levels (PMID: 15987702). -
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityMar 29, 2023- -
Likely pathogenic, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenNov 01, 2024FH: PM3:Strong, PS3:Moderate, PM2:Supporting -
Uncertain significance, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoJun 06, 2024- -
Pathogenic, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Jan 20, 2015- -
Uncertain significance, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicJul 16, 2020- -
Uncertain significance, no assertion criteria providedresearchBiesecker Lab/Clinical Genomics Section, National Institutes of HealthJul 13, 2012- -
Likely pathogenic, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesSep 14, 2023The FH c.1431_1433dupAAA; p.Lys477dup variant (rs367543046), also known as Lys434ins, 1302insAAA, 1431insAAA, 1433_1434dupAAA, is commonly found in the compound heterozygous state in individuals with fumarase deficiency (Coughlin 1998, Ezgu 2013, Rustin 1997), and is considered the most frequent pathogenic variant associated with fumarase deficiency (Ewbank 2013). It is also reported in the heterozygous state in individuals with cancer predisposition syndrome including hereditary leiomyomatosis and renal cell cancer syndrome (Chen 2014, Ezgu 2013, Martinek 2015, Whitworth 2018). This variant is reported in ClinVar (Variation ID: 42095). It is found in the general population with an overall allele frequency of 0.1% (285/280892 alleles, including 2 homozygotes) in the Genome Aggregation Database. Based on available information, this variant is considered to be likely pathogenic. REFERENCES Chen YB et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol. 2014 May;38(5):627-37. Coughlin EM et al. Molecular analysis and prenatal diagnosis of human fumarase deficiency. Mol Genet Metab. 1998 Apr;63(4):254-62. Ewbank C et al. Fumarate Hydratase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. SourceGeneReviews (Internet). Seattle (WA): University of Washington, Seattle; 1993-2019. 2006 Jul 5 (updated 2013 Apr 4). Accessed online at: https://www.ncbi.nlm.nih.gov/books/NBK1506/ Ezgu F et al. Mild clinical presentation and prolonged survival of a patient with fumarase deficiency due to the combination of a known and a novel mutation in FH gene. Gene. 2013 Jul 25;524(2):403-6. Martinek P et al. Genetic testing of leiomyoma tissue in women younger than 30 years old might provide an effective screening approach for the hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC). Virchows Arch. 2015 Aug;467(2):185-91. Rustin P et al. Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human. Biochim Biophys Acta. 1997 Aug 22;1361(2):185-97. Whitworth J et al. Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. Am J Hum Genet. 2018 Jul 5;103(1):3-18. -
Likely pathogenic, criteria provided, single submitterclinical testingInstitute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU DresdenNov 03, 2021- -
Pathogenic, no assertion criteria providedclinical testingGenome Diagnostics Laboratory, Amsterdam University Medical Center-- -
Fumarase deficiency Pathogenic:2Uncertain:1Other:1
not provided, no classification providedliterature onlyGeneReviews-- -
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsMar 30, 2024- -
Uncertain significance, criteria provided, single submitterclinical testingInstitute of Human Genetics, University of Leipzig Medical CenterApr 25, 2017- -
Pathogenic, no assertion criteria providedliterature onlyOMIMAug 07, 2020- -
Hereditary leiomyomatosis and renal cell cancer Pathogenic:2Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingSt. Jude Molecular Pathology, St. Jude Children's Research HospitalDec 01, 2023This variant is considered likely benign with respect to hereditary leiomyomatosis and renal cell cancer (HLRCC; OMIM ID: 150800). However it may predispose to fumarate hydratase (FH) deficiency (OMIM ID: 606812) when detected in trans with a pathogenic variant (compound heterozygous), but not when detected in the homozygous state. Functional studies have not interrogated the role of this variant in the absence of a second pathogenic variant, and therefore we consider its role in disease to be unclear. -
Likely pathogenic, criteria provided, single submitterclinical testingMGZ Medical Genetics CenterAug 19, 2022- -
Pathogenic, criteria provided, single submitterclinical testingMendelicsMay 04, 2022- -
Hereditary cancer-predisposing syndrome Pathogenic:1Benign:1
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsMay 04, 2023The c.1431_1433dupAAA (p.K477dup) alteration, located in coding exon 10 of the FH gene, results from an in-frame duplication of 3 nucleotides at positions 1431 to 1433. This results in the duplication of a lysine residue at codon 477. This alteration is also designated as K434ins, c.1302insAAA, c.1433dupAAA, AAAins435, 435insK, 435insAAA, c.1433_1434dupAAA, and c.1431insAAA in published literature. Based on the available evidence, the FH c.1431_1433dupAAA (p.K477dup) alteration is classified as pathogenic in the compound heterozygous state for autosomal recessive FH deficiency; however, it is not considered a risk factor for HLRCC. Based on data from gnomAD, the c.1431_1433dupAAA allele has an overall frequency of 0.102% (285/280892) total alleles studied. The highest observed frequency was 0.512% (53/10360) of Ashkenazi Jewish alleles. This alteration has been identified in a suspected or confirmed compound heterozygous state with other FH alterations in numerous children with autosomal recessive fumarate hydratase (FH) deficiency (Gellera, 1990; Rustin, 1997; Coughlin, 1998; Loeffen, 2005; Pollard, 2005; Deschauer, 2006; Ottolenghi, 2011; Ezgu, 2013; Tregoning, 2013). However, this variant has been detected incidentally in a homozygous state in individuals who do not have features that are consistent with FH deficiency, although they may not have been ascertained for FH-related diseases (Ambry internal data). In the literature, this variant has been detected in a heterozygous state in a few individuals who have some features that are consistent with autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) including renal cancer, uterine leiomyomas and subcutaneous leiomyomas, although at least one of these individuals carried another FH alteration (phase unknown) (Chen, 2014; Martínek, 2015; Ylisaukko-oja, 2006; Ezgu, 2013). However, this variant has also been detected in a heterozygous state in a vast number of individuals who do not have a personal or family history that is consistent with or suggestive of HLRCC (Zhang, 2020; Forde, 2020; Pahl, 2018; Ambry internal data). This amino acid position is well conserved in available vertebrate species. A cell line derived from a patient with FH deficiency, who is compound heterozygous for this alteration and FH p.R233H, showed defective energy and redox metabolism at the mRNA level (Raimundo, 2008). This alteration is predicted to be deleterious by in silico analysis (Choi, 2012). Based on the available evidence, this alteration is classified as pathogenic. -
Likely benign, flagged submissioncurationSema4, Sema4Nov 02, 2021- -
not specified Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpAug 15, 2024Variant summary: FH c.1431_1433dupAAA (p.Lys477dup) results in a duplication of a lysine residue in the Fumarase C, C-terminal domain (IPR018951) of the encoded protein sequence. The variant allele was found at a frequency of 0.0019 in 1613964 control chromosomes in the gnomAD database (v4), including 8 homozygotes. The observed variant frequency is approximately 2 fold of the estimated maximal expected allele frequency for a pathogenic variant in FH causing Fumarate Hydratase Deficiency phenotype (0.0011). Due to its high frequency, c.1431_1433dupAAA has been reported in the literature in multiple individuals affected with features of Hereditary Leiomyomatosis and Renal Cell Cancer (example, Ezgu_2013, Ylisaukko-oja_2006, BeiChen_2014, Martinek_2015), multiple primary tumors (Whitworth_2018, Carlo_2020, Hartman_2020), in a study examining cancer susceptibility variants in subjects with atherosclerosis phenotypes (ClinSeq cohort, Johnston_2012) and in compound heterozygous genotypes with other FH variants in case reports of patients with biochemically and clinically confirmed Fumarase deficiency (example, Tregoning_2013, Deschauer_2006, Loeffen_2005, Coughlin_1998, Prasad_2017). To our knowledge, no homozygous patients affected with classic Fumarase deficiency have been ascertained. In 2002, the Multiple Leiomyoma Consortium identified FH as a non-classical tumor suppressor gene responsible for multiple cutaneous and uterine leiomyomas (MCUL) as well as hereditary leiomyomatosis and renal cell cancer (HLRCC) (as cited in Ezgu_2013). However, two recent studies provide evidence that c.1431_1433dupAAA is not associated with Renal Cell Cancer (RCC): in a large US cancer cohort of 7571 patients, none of the renal cell cancer patients carried the variant of interest (Zhang_2020). In a following case study of 2 carriers with renal cell carcinoma, immunohistochemistry-based analysis of patient tumors revealed no FH-deficiency with the authors concluding that this variant may not contribute to RCC (Gupta_2021). Several publications report experimental evidence evaluating an impact on FH activity in compound heterozygous genotypes (example, Tregoning_2013, Loeffen_2005, Pollard_2005, Coughlin_1998). However, these reports do not allow convincing conclusions about the variant effect due to lack of homozygous control activity measurements. The following publications have been ascertained in the context of this evaluation (PMID: 15987702, 22703879, 29909963, 24441663, 9635293, 16510303, 23612258, 16151915, 25985877, 27541980, 24182348, 16639410, 31444830, 32782288, 31794323, 34337822). ClinVar contains an entry for this variant (Variation ID: 42095). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic for Fumarase deficiency when observed in combination with other pathogenic/likely pathogenic variants in the FH gene. -
Uncertain significance, criteria provided, single submitterclinical testingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University HospitalJul 31, 2024- -
Fumarase deficiency;C1708350:Hereditary leiomyomatosis and renal cell cancer Pathogenic:1
Likely pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsJun 17, 2024- -
FH-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria providedclinical testingPreventionGenetics, part of Exact SciencesJan 04, 2024The FH c.1431_1433dupAAA variant is predicted to result in an in-frame duplication (p.Lys477dup). This variant has been reported in the heterozygous state in individuals with hereditary leiomyomatosis and renal cell cancer (Chen et al. 2014. PubMed ID: 24441663; Martínek et al. 2015. PubMed ID: 25985877); however it has also been observed in many unaffected individuals (Ylisaukko-oja et al. 2006. PubMed ID: 16639410; Johnston et al. 2012. PubMed ID: 22703879, Table S1; Zhang et al. 2020. PubMed ID: 31444830). In the gnomAD database, this variant has been observed in the Ashkenazi Jewish population at an allele frequency of 0.5%, and it is documented in two homozygous individuals in gnomAD. This duplication has been reported as causative for autosomal recessive fumarase deficiency when found in the compound heterozygous state with a second pathogenic FH variant, but has not been documented as causative in the homozygous state (Rustin et al. 1997. PubMed ID: 9300800; Coughlin et al. 1998. PubMed ID: 9635293; Deschauer et al. 2006. PubMed ID: 16510303; Tregoning S et al 2013. PubMed ID: 24182348). In ClinVar, this variant is reported as uncertain significance, likely pathogenic, and pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/42095/) . We classify the FH c.1431_1433dup (p.Lys477dup) variant as likely pathogenic in the context of fumarase deficiency, when found in the compound heterozygous state. The c.1431_1433dup (p.Lys477dup) variant in the homozygous state, is less likely to contribute to disease. This variant is unlikely to be pathogenic for hereditary leiomyomatosis and renal cell cancer and in the context of autosomal dominant phenotypes, this alteration is classified as a variant of uncertain significance. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs367543046; hg19: chr1-241661227; API